France · Delayed Price · Currency is EUR Eurofins Scientific SE Earnings Call Transcripts
Fiscal Year 2026
-
Strong H1 2026 results featured 29% EPS growth and margin expansion, driven by operational efficiencies, portfolio focus, and disciplined capital allocation. Despite Biopharma softness, guidance for mid-single-digit organic growth and margin improvement is reaffirmed.
-
Q1 revenue growth was hampered by severe weather, but March rebounded to mid-single digits. Management maintains full-year mid-single-digit organic growth guidance and expects continued margin improvement, supported by digitalization and portfolio optimization.
Fiscal Year 2025
-
Strong 2025 performance with all objectives met or exceeded, driven by margin expansion, robust EPS and free cash flow growth, and accelerating organic revenue. Major investments in IT and site ownership are nearing completion, supporting future growth and operational efficiency. Continued share buybacks and M&A are expected, with biopharma and core segments poised for recovery and expansion.
-
Progress on network expansion and digitalization is on track, with margin improvements and strong cash flow expected. BioPharma and Life segments are performing well, while genomics and agroscience are stabilizing. FX headwinds are minor, and buybacks remain a capital allocation priority.
-
H1 2025 saw strong revenue, margin, and EPS growth, with mature business margins at target levels and ongoing investments in infrastructure and digitalization. Management remains confident in achieving 2027 targets, with biopharma recovery and further efficiency gains expected.
-
Q1 2025 delivered strong organic growth in food and environmental testing, with U.S. weather disruptions expected to be offset later in the year. Major Spanish acquisition and IT investments are underway, while guidance and capital allocation priorities remain unchanged.
Fiscal Year 2024
-
FY 2024 saw robust revenue and margin growth, with strong cash flow and disciplined CapEx. Mature businesses neared target margins, while BioPharma and Agroscience faced temporary softness. Long-term growth and margin targets are reaffirmed, with share buybacks prioritized.
-
Q3 saw softer growth due to BioPharma and Agroscience weakness, but margins and profitability exceeded plans. Share buybacks increased as M&A slowed, and 2027 growth targets remain on track, with BioPharma recovery expected in 2025.
-
Strong H1 2024 results featured 6.5% revenue growth, 21% EBITDA increase, and 220 bps margin expansion, despite ongoing investment and biopharma softness. Robust cash flow and reduced leverage support continued share buybacks and strategic investments.